Effects of pioglitazone or metformin on bone markers and bone mineral density as well as parameters of atherosclerosis in patients with type 2 diabetes

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2009
INTERVENTION: Pioglitazone Metformin CONDITION: Type 2 diabetes mellitus PRIMARY OUTCOME: bone turnover marker, bone mineral density, intima‐media thickness, pulse wave velocity INCLUSION CRITERIA: Patients with Type 2 diabetes
Epistemonikos ID: 079a97000740a5d4c3d60b8652fe4d2da4a4e374
First added on: Aug 22, 2024